[1] Charest M, Armanious S. Prognostic implication of the lymphangitic carcinomatosis pattern on perfusion lung scan[J]. Can Assoc Radiol J, 2012, 63(4):294-303. DOI:10.1016/j.carj.2011.04.004.
[2] Bhattacharya PK, Jamil M, Khonglah Y, et al. A Rare Case of Pulmonary Lymphangitic Carcinomatosis in a Young Adult with Carcinoma Stomach[J]. J Clin Diagn Res, 2017, 11(8):OD07-OD09. DOI:10.7860/JCDR/2017/27352.10397.
[3] Lee SJ, Lee J, Yu SJ, et al. Timely diagnosis of pulmonary artery tumor embolism by ultrasound-guided transbronchial needle aspiration[J]. Thorac Cancer, 2014, 5(2):184-187. DOI:10.1111/1759-7714.12062.
[4] Gorshein E, Burger R, Ferrari A, et al. Dramatic mixed response of lymphangitic pulmonary metastases in newly diagnosed prostate cancer[J]. Urol Ann, 2017, 9(3):278-280.DOI:10.4103/UA.UA_21_17.
[5]

Moubax K, Wuyts W, Vandecaveye V, et al. Pulmonary lymphangitic carcinomatosis as a primary manifestation of gastric carcinoma in a young adult: a case report and review of the literature[J/OL]. BMC Res Notes, 2012, 5: 638[2018-01-01]. https: //www. ncbi. nlm. nih. gov/pmc/articles/PMC3519516. DOI: 10.1186/1756-0500-5-638.
[6] Vattimo AV, Burroni L, Bertelli P, et al. The 'fragmented' scintigraphic lung pattern in pulmonary lymphangitic carcinomatosis secondary to breast cancer[J]. Respiration, 1998, 65(5):406-410. DOI:10.1159/000029304.
[7] Kashitani N, Eda R, Masayoshi T, et al. Lobar extent of pulmonary lymphangitic carcinomatosis. Tl-201 chloride and Tc-99m MIBI scintigraphic findings[J]. Clin Nucl Med, 1996, 21(9):726-729.  doi: 10.1097/00003072-199609000-00011
[8] 王宏伟, 陆江阳, 王晓虹, 等.肺淋巴管癌病8例尸检临床病理学观察[J].诊断病理学杂志, 2005, 12(3):174-177. DOI:10.3969/j.issn.1007-8096.2005.03.005.
Wang HW, Lu JY, Wang XH, et al. Clinicopathological features of pulmonary lymphangitic carcinomatosis:a report of 8 autopsied cases[J]. Chin J Diagn Pathol, 2005, 12(3):174-177.  doi: 10.3969/j.issn.1007-8096.2005.03.005
[9] 肖燕, 王海燕, 王宏伟, 等.肺淋巴管癌病误诊病例回顾性分析[J].中国肺癌杂志, 2007, 10(1):54-57.
Xiao Y, Wang HY, Wang HW, et al. Misdiagnosis analysis of pulmonary lymphomatosis carcinomatous[J]. Chin J Lung Cancer, 2007, 10(1):54-57.
[10] Oikonomou A, Prassopoulos P. Mimics in chest disease:interstitial opacities[J]. Insights Imaging, 2013, 4(1):9-27. DOI:10.1007/s13244-012-0207-7.
[11] Godbole R, Ghatol A, Betancourt J, et al. Pulmonary Tumor Thrombotic Microangiopathy:Clinical, Radiologic, and Histologic Correlation[J]. J Clin Imaging Sci, 2015, 5:44. DOI:10.4103/2156-7514.161978.
[12] Park SB, Choi JY, Moon SH, et al. Prognostic value of volumetric metabolic parameters measured by[18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer[J]. Cancer Imaging, 2014, 14:2. DOI:10.1186/1470-7330-14-2.
[13] Chung HW, Lee KY, Kim HJ, et al. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma[J]. J Cancer Res Clin Oncol, 2014, 140(1):89-98. DOI:10.1007/s00432-013-1545-7.
[14] Ooi H, Chen CY, Hsiao YC, et al. Fluorodeoxyglucose Uptake in Advanced Non-small Cell Lung Cancer With and Without Pulmonary Lymphangitic Carcinomatosis[J]. Anticancer Res, 2016, 36(8):4313-4320.
[15] Digumarthy SR, Fischman AJ, Kwek BH, et al. Fluorodeoxyglucose positron emission tomography pattern of pulmonary lymphangitic carcinomatosis[J]. J Comput Assist Tomogr, 2005, 29(3):346-349.  doi: 10.1097/01.rct.0000163952.03192.ef
[16] Acikgoz G, Kim SM, Houseni M, et al. Pulmonary lymphangitic carcinomatosis(PLC):spectrum of FDG-PET findings[J]. Clin Nucl Med, 2006, 31(11):673-678. DOI:10.1097/01.rlu.0000242210. 99022.fd.
[17] Prakash P, Kalra MK, Sharma A, et al. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis[J]. AJR Am J Roentgenol, 2010, 194(1):231-236. DOI:10.2214/AJR.09.3059.
[18] Oikonomou A, Prassopoulos P. Mimics in chest disease:interstitial opacities[J]. Insights Imaging, 2013, 4(1):9-27. DOI:10.1007/s13244-012-0207-7.